Skip to main content

Recombinant Cynomolgus 4-1BB/TNFRSF9 Fc Chimera Protein, CF

Bio-Techne includes R&D Systems | Catalog # 9324-4B

Catalog #
Availability
Size / Price
Qty
Loading...
9324-4B-100

Key Product Details

Source

HEK293

Accession #

Structure / Form

Disulfide-linked homodimer

Conjugate

Unconjugated

Applications

Bioactivity

Product Specifications

Source

Human embryonic kidney cell, HEK293-derived cynomolgus monkey 4-1BB/TNFRSF9/CD137 protein
Cynomolgus Monkey 4-1BB/TNFRSF9
(Leu24-Gln186)
Accession # XP_005544945
IEGRMD Human IgG1
(Pro100-Lys330)
N-terminus C-terminus

Purity

>95%, by SDS-PAGE visualized with Silver Staining and quantitative densitometry by Coomassie® Blue Staining.

Endotoxin Level

<0.10 EU per 1 μg of the protein by the LAL method.

N-terminal Sequence Analysis

Leu24

Predicted Molecular Mass

44 kDa

SDS-PAGE

56-66 kDa, reducing conditions

Activity

Measured by its binding ability in a functional ELISA.
When Recombinant Cynomolgus Monkey 4-1BB/TNFRSF9/CD137 Fc Chimera is immobilized at 0.05 µg/mL (100 µL/well), Recombinant Human 4-1BB Ligand/TNFSF9 (Catalog # 2295-4L) binds with an ED50 of 0.25-1.25 ng/mL.

Scientific Data Images for Recombinant Cynomolgus 4-1BB/TNFRSF9 Fc Chimera Protein, CF

Recombinant Cynomolgus 4-1BB/TNFRSF9 Fc Chimera Protein Bioactivity

Recombinant Cynomolgus 4-1BB/TNFRSF9 Fc Chimera Protein Bioactivity

When Recombinant Cynomolgus Monkey 4-1BB/TNFRSF9 Fc Chimera is coated at 0.05 µg/mL, 100 µL/well, Recombinant Human 4-1BB Ligand/TNFSF9 (Catalog # 2295-4L) binds with an ED50 of 0.25-1.25 ng/mL.

Formulation, Preparation and Storage

9324-4B
Formulation Lyophilized from a 0.2 μm filtered solution in PBS.
Reconstitution
Reconstitute at 500 μg/mL in PBS.

Reconstitution Buffer Available:
Size / Price
Qty
Loading...
Shipping The product is shipped at ambient temperature. Upon receipt, store it immediately at the temperature recommended below.
Stability & Storage Use a manual defrost freezer and avoid repeated freeze-thaw cycles.
  • 12 months from date of receipt, -20 to -70 °C as supplied.
  • 1 month, 2 to 8 °C under sterile conditions after reconstitution.
  • 3 months, -20 to -70 °C under sterile conditions after reconstitution.

Background: 4-1BB/TNFRSF9/CD137

4-1BB, also known as CD137 and TNFRSF9, is an approximately 30 kDa transmembrane glycoprotein in the TNF receptor superfamily. 4-1BB functions in the development and activation of multiple immune cells (1). Mature human 4-1BB consists of a 163 amino acid (aa) extracellular domain (ECD) with four TNFR cysteine‑rich repeats, a 27 aa transmembrane segment, and a 42 aa cytoplasmic domain (2, 3). Within the ECD, cynomolgus 4-1BB shares 95%, 57%, and 57% aa sequence identity with human, mouse, and rat 4-1BB, respectively. 4-1BB is expressed as a disulfide-linked homodimer on various populations of activated T cell including CD4+, CD8+, memory CD8+, NKT, and regulatory T cells (4-7) as well as on myeloid and mast cell progenitors, dendritic cells, mast cells, and bacterially infected osteoblasts (8-11). It binds with high affinity to the transmembrane 4-1BB Ligand/TNFSF9 which is expressed on antigen presenting cells and myeloid progenitor cells (3, 8). This interaction co-stimulates the proliferation, activation, and/or survival of the 4-1BB expressing cell (3-7). It can also enhance the activation-induced cell death of repetitively stimulated T cells (3). Mice lacking 4-1BB show augmented T cell activation, perhaps due to its absence on regulatory T cells (12).
4-1BB can associate with OX40 on activated T cells, forming a complex that responds to either ligand and inhibits Treg and CD8+ T cell proliferation (13). Reverse signaling through 4-1BB Ligand inhibits the development of dendritic cells, B cells, and osteoclasts (8, 11) but supports mature dendritic cell survival and co‑stimulates the proliferation and activation of mast cells (9, 10). 4-1BB activation enhances CD8+ T cell and NK cell mediated anti-tumor immunity (14). It also contributes to the development of inflammation in high fat diet-induced metabolic syndrome (15). Soluble forms of 4-1BB and 4-1BB Ligand circulate at elevated levels in the serum of rheumatoid arthritis and hematologic cancer patients, respectively (16, 17).

References

  1. Wang, C. et al. (2009) Immunol. Rev. 229:192.
  2. Schwarz, H. et al. (1993) Gene 134:295.
  3. Alderson, M.R. et al. (1994) Eur. J. Immunol. 24:2219.
  4. Wen, T. et al. (2002) J. Immunol. 168:4897.
  5. Pulle, G. et al. (2006) J. Immunol. 176:2739.
  6. Zheng, G. et al. (2004) J. Immunol. 173:2428.
  7. Kim, D. et al. (2008) J. Immunol. 180:2062.
  8. Lee, S. et al. (2008) Nat. Immunol.9:917.
  9. Choi, B.K. et al. (2009) J. Immunol. 182:4107.
  10. Nishimoto, H. et al. (2005) Blood 106:4241.
  11. Saito, K. et al. (2004) J. Biol. Chem. 279:13555.
  12. Lee, S. et al. (2005) J. Immunol. 174:6803.
  13. Ma, B.Y. et al. (2005) Blood 106:2002.
  14. Choi, B.K. et al. (2010) J. Immunol. 185:1404.
  15. Kim, C. et al. (2011) Diabetes 60:3159.
  16. Michel, J. et al. (1998) Eur. J. Immunol. 28:290.
  17. Salih, H.R. et al. (2001) J. Immunol. 167:4059.

Alternate Names

41BB, CD137, ILA, TNFRSF9

Entrez Gene IDs

3604 (Human); 21942 (Mouse); 500590 (Rat); 102127961 (Cynomolgus Monkey)

Gene Symbol

TNFRSF9

UniProt

Additional 4-1BB/TNFRSF9/CD137 Products

Product Documents for Recombinant Cynomolgus 4-1BB/TNFRSF9 Fc Chimera Protein, CF

Certificate of Analysis

To download a Certificate of Analysis, please enter a lot number in the search box below.

Note: Certificate of Analysis not available for kit components.

Product Specific Notices for Recombinant Cynomolgus 4-1BB/TNFRSF9 Fc Chimera Protein, CF

For research use only

Loading...
Loading...